Journal article
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
O Pagani, MM Regan, BA Walley, GF Fleming, M Colleoni, I Láng, HL Gomez, C Tondini, HJ Burstein, EA Perez, E Ciruelos, V Stearns, HR Bonnefoi, S Martino, CE Geyer, G Pinotti, F Puglisi, D Crivellari, T Ruhstaller, EP Winer Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2014
Abstract
BACKGROUND: Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor- positive breast cancer. METHODS: In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early breast cancer to the aromatase inhibitor exemestane plus ovarian suppression or tamoxifen plus ovarian suppression for a period of 5 years. Suppression of ovarian estrogen production was achieved with the use of the gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, or ovarian irradiation. The primary analysis combined data from 4690 patients in the two trials. RESULTS: After a median follow-up of..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by Pfizer, Ipsen, the International Breast Cancer Study Group, and the National Cancer Institute. Dr. Fleming reports receiving a study drug for investigation in a clinical trial from Corcept Therapeutics; Dr. Colleoni, receiving fees for serving on advisory boards from Boehringer Ingelheim, Taiho Pharmaceutical, AbbVie, and AstraZeneca and consulting and lecture fees from Novartis; Dr. Stearns, receiving grant support from Pfizer and Novartis; Dr. Ruhstaller, receiving travel support and fees for serving on an advisory board from Novartis; and Dr. Viale, receiving fees for serving on advisory boards from Novartis, Roche, and Eli Lilly. No other potential conflict of interest relevant to this article was reported.